About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

CellCentric to Participate in Upcoming Investor Conferences

By: Newsfile

Cambridge, United Kingdom and Boston, Massachusetts--(Newsfile Corp. - August 5, 2025) -  CellCentric, a privately held biotechnology company developing inobrodib, a first-in-class p300/CBP inhibitor for multiple myeloma, today announced that members of its senior management team will participate in several upcoming investor conferences.

These events provide an opportunity to engage with the investment community and highlight the company's clinical progress with inobrodib, which will be entering a potentially registration enabling study later this year.

Upcoming appearances include:

  • Oppenheimer & Co.'s 2025 Biotech in the Berkshires, Berkshires, MA
    Presentation time: Tuesday, August 5, 2025, 11:51am ET
  • Citi's 2025 Biopharma Back to School Conference, Boston, MA
    1x1s only: Tuesday, September 2, 2025
  • 2025 Wells Fargo Healthcare Conference, Boston, MA
    Presentation time: September 3, 10:15am ET
  • Cantor Global Healthcare Conference, New York, NY
    1x1s only: September 4, 2025
  • Morgan Stanley Health Care Conference, New York, NY
    Presentation time: September 8, 2025, 3:20pm ET
  • BofA Securities Healthcare Trailblazers Private Company Conference, Boston, MA
    1x1s only: September 17, 2025

For more information or to request a meeting, please contact: IR@cellcentric.com

About inobrodib

Inobrodib is a potential new treatment for people with cancer, and multiple myeloma in particular. It is a small molecule drug that targets p300/CBP, lowering the expression of key cancer drivers, including MYC and IRF4. It has been evaluated in over 400 patients to date and has a favourable safety and tolerability profile. Clinical activity has been seen in multiple settings, both solid tumour and hematologic malignancies. Delivered as an oral capsule, it is easy for patients to take and can be used at home without the need for intensive monitoring. Its differentiated profile may broaden use among patients who cannot tolerate or access other treatments, while its ease of administration could reduce healthcare system burden relative to more complex therapies.

About CellCentric
CellCentric is a privately held biotechnology company advancing inobrodib, a first-in-class, orally bioavailable p300/CBP inhibitor. Inobrodib is in a Phase II clinical trial for patients with relapsed/refractory multiple myeloma, with additional indications under consideration. CellCentric is supported by a robust IP portfolio and external validation through clinical collaborations and strategic partnerships. Headquartered in the UK with expanding U.S. operations, CellCentric is backed by a global syndicate of life science investors, including RA Capital, Forbion (including ForCal), Morningside, Pfizer Ventures, Avego, and the American Cancer Society's BrightEdge Fund. For more information, please visit: www.cellcentric.com.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261279

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.